• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by ViewRay Inc. (Amendment)

    7/21/23 4:30:07 PM ET
    $VRAY
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $VRAY alert in real time by email
    SC 13D/A 1 tm2321767d1_sc13da.htm SC 13D/A

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13D 

    (Rule 13d-101)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT 

    TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED 

    PURSUANT TO RULE 13d-2(a)

     

    Under the Securities Exchange Act of 1934 

    (Amendment No. 3)*

     

    ViewRay, Inc. 

    (Name of Issuer)

     

    Common Stock, $0.01 par value 

    (Title of Class of Securities)

     

    92672L107 

    (CUSIP Number)

     

    Jeremy Nierman 

    Hudson Executive Capital LP 

    c/o Cadwalader, Wickersham & Taft LLP
    200 Liberty Street 

    New York, NY 10281 

    (212) 521-8495

     

    With a copy to:

     

    Richard M. Brand 

    Michael Pinnisi 

    Cadwalader, Wickersham & Taft LLP 

    200 Liberty Street 

    New York, NY 10281 

    212-504-6000 

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    July 19, 2023 

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 92672L107   Page 2

     

    1

    NAME OF REPORTING PERSON

     

    Hudson Executive Capital LP

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) ¨

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    OO

     

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨

     

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

     

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with

    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    6,752,093

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    6,752,093 

     

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    6,752,093

     

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    3.68%*

     

    14

    TYPE OF REPORTING PERSON

     

    PN, IA 

     

     

    * All percentage calculations set forth herein are based upon the aggregate of 183,402,038 shares of Common Stock outstanding as of April 28, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on May 11, 2023.

     

     

     

     

    CUSIP No. 92672L107   Page 3

     

    1

    NAME OF REPORTING PERSON

     

    HEC Management GP LLC

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) ¨

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    OO

     

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨

     

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

     

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with

    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    6,752,093

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    6,752,093 

     

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    6,752,093

     

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    3.68%*

     

    14

    TYPE OF REPORTING PERSON

     

    PN, IA

     

     

    * All percentage calculations set forth herein are based upon the aggregate of 183,402,038 shares of Common Stock outstanding as of April 28, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023.

     

     

     

     

    CUSIP No. 92672L107   Page 4

     

    1

    NAME OF REPORTING PERSON

     

    Douglas L. Braunstein

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) ¨

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    OO

     

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨

     

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with

    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    6,752,093

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    6,752,093

     

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    6,752,093

     

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    3.68%*

     

    14

    TYPE OF REPORTING PERSON

     

    IN

     

     

    * All percentage calculations set forth herein are based upon the aggregate of 183,402,038 shares of Common Stock outstanding as of April 28, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023.

     

     

     

     

     CUSIP No. 92672L107   Page 5

     

    ITEM 1. SECURITY AND ISSUER

     

    This Amendment No. 3 to the Schedule 13D (this “Amendment No. 3”) amends and supplements the Schedule 13D filed by the Reporting Persons with the SEC on February 24, 2020 (as amended and supplemented through the date of this Amendment No. 3, the “Schedule 13D”), relating to their beneficial ownership in the common stock, par value $0.01 per share (the “Shares”) of ViewRay, Inc., a corporation organized under the laws of the State of Delaware (the “Issuer”). Capitalized terms used but not defined in this Amendment No. 3 shall have the respective meanings ascribed to them in the Schedule 13D.

     

    This Amendment No. 3 is being filed to report a decrease in the Reporting Persons’ beneficial ownership percentage due to the sale of Shares by the Reporting Persons. The Reporting Persons beneficially own an aggregate of 6,752,093 Shares (the “Subject Shares”). The Subject Shares represent approximately 3.68% of the issued and outstanding Shares based on 183,402,038 Shares outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023.

     

    ITEM 5.INTEREST IN SECURITIES OF THE ISSUER

     

    Item 5 (a), (b), (c) and (e) of the Schedule 13D are hereby amended and supplemented by adding the following information:

     

    (a) and (b) Information about the number and percentage of Shares beneficially owned by the Reporting Persons is set forth in Item 1, and that information is incorporated by reference herein.

     

    (c) All transactions in the Shares effected by the Reporting Persons during the past sixty days are set forth in Exhibit 5 attached hereto and incorporated herein by reference.

     

    (e) Following the transactions described on Exhibit 5 hereto, each of the Reporting Persons ceased to be a beneficial owner of more than five percent of the Issuer’s Shares.

     

    ITEM 7. MATERIAL TO BE FILED AS AN EXHIBIT

     

    Exhibit 5 Schedule of transactions effected by the Reporting Persons during the past sixty days.

     

     

     

     

     CUSIP No. 92672L107   Page 6

     

    SIGNATURES

     

    After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Date: July 21, 2023

     

    HUDSON EXECUTIVE CAPITAL LP  
       
    By: HEC Management GP LLC, its general partner  
         
    By: /s/ Douglas L. Braunstein  
      Name: Douglas L. Braunstein  
      Title: Managing Member  

     

    HEC MANAGEMENT GP LLC  
         
    By: /s/ Douglas L. Braunstein  
      Name: Douglas L. Braunstein  
      Title: Managing Member  

     

    DOUGLAS L. BRAUNSTEIN  
       
    /s/ Douglas L. Braunstein  
    Douglas L. Braunstein  

     

     

     

     

    INDEX TO EXHIBITS

     

    Exhibit  Description
       
    Exhibit 5 Schedule of transactions effected by the Reporting Persons during the past sixty days.

     

     

     

     

    EXHIBIT 5

     

    Schedule of Transactions in Shares

     

    The following table sets forth all transactions with respect to Shares effected by the Reporting Persons or on behalf of the Reporting Persons in respect of the Shares during the past sixty days.

     

    ViewRay, Inc.

     

    Trade Date  Transaction  Security  Quantity Bought
    (Sold)
       Unit Cost (1) 
    7/19/2023  Sell  Common Stock   (4,000,000)  $0.07 
    7/20/2023  Sell  Common Stock   (2,000,000)  $0.06 
    7/21/2023  Sell  Common Stock   (3,000,000)  $0.05 

    (1) Excludes brokerage commissions and other costs of execution.

     

     

     

     

    Get the next $VRAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VRAY

    DatePrice TargetRatingAnalyst
    5/11/2023$4.00 → $1.00Buy → Neutral
    B. Riley Securities
    4/17/2023$7.00 → $1.25Buy → Hold
    Jefferies
    4/14/2023Outperform → Perform
    Oppenheimer
    4/14/2023Buy → Neutral
    BTIG Research
    4/14/2023$7.00 → $1.75Buy → Hold
    Stifel
    1/25/2022$7.00Buy
    Stifel
    1/11/2022$7.00Neutral → Buy
    B. Riley Securities
    10/14/2021$7.00Neutral
    B. Riley Securities
    More analyst ratings

    $VRAY
    Leadership Updates

    Live Leadership Updates

    See more
    • NUBURU Appoints Brian Knaley as new CEO

      NUBURU, Inc. ("NUBURU" or the "Company") (NYSE:BURU), a leading innovator in high-power and high-brightness industrial blue laser technology, today announced the appointment of Brian Knaley as the Company's new Chief Executive Officer, replacing Dr. Mark Zediker, who has left the Company to pursue other opportunities. Mr. Knaley has also joined NUBURU's Board of Directors upon assuming the role. Mr. Knaley, who had served as the Company's Chief Financial Officer since February 2022, has over 25 years of experience in finance and operations. Prior to joining NUBURU, Mr. Knaley served as the chief financial officer of CEA Industries Inc. (NASDAQ:CEAD), a provider of controlled environmental

      11/1/23 4:30:00 PM ET
      $BURU
      $CEAD
      $VRAY
      Industrial Machinery/Components
      Miscellaneous
      Industrials
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • ViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. "Bill" Burke as Chief Financial Officer

      DENVER, Jan. 9, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2022. The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 2022 Preliminary Results and Other Data (Unaudited)Received nine new orders for MRIdian systems totaling approximately $56 million, compared to seven new orders totaling approximately $41 million in the fourth quarter of 2021. A total of 32 orders were received for the twelve months ended December 31, 2022, compared to 28 orders for the twelve months ended December 31, 2021. Total backlog i

      1/9/23 6:00:00 AM ET
      $AXGN
      $MIRO
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • NUBURU Names Brian Knaley as Chief Financial Officer

      Three-time public company CFO joins NUBURU with deep experience in leading business transformation and optimization of financial processes on a global scale NUBURU®, the industry leader in high power and high brightness industrial blue lasers, today announced that it has appointed Brian Knaley as Chief Financial Officer. In this strategic role, Mr. Knaley will oversee all aspects of finance and investor relations as NUBURU accelerates and implements its growth strategy to expand the presence of its blue laser technology across target markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322005131/en/Three-time public compan

      3/22/22 9:00:00 AM ET
      $CEAD
      $VRAY
      Industrial Machinery/Components
      Industrials
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VRAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NUBURU Appoints Brian Knaley as new CEO

      NUBURU, Inc. ("NUBURU" or the "Company") (NYSE:BURU), a leading innovator in high-power and high-brightness industrial blue laser technology, today announced the appointment of Brian Knaley as the Company's new Chief Executive Officer, replacing Dr. Mark Zediker, who has left the Company to pursue other opportunities. Mr. Knaley has also joined NUBURU's Board of Directors upon assuming the role. Mr. Knaley, who had served as the Company's Chief Financial Officer since February 2022, has over 25 years of experience in finance and operations. Prior to joining NUBURU, Mr. Knaley served as the chief financial officer of CEA Industries Inc. (NASDAQ:CEAD), a provider of controlled environmental

      11/1/23 4:30:00 PM ET
      $BURU
      $CEAD
      $VRAY
      Industrial Machinery/Components
      Miscellaneous
      Industrials
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • ViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Markets

      DENVER, July 21, 2023 /PRNewswire/ -- ViewRay, Inc. (the "Company") (NASDAQ:VRAY) announced today that on July 17, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"). Nasdaq has determined that due to the Company's voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code, and concerns about the Company's ability to sustain compliance with the $1.00 per share minimum bid price requirement for continued inclusion on Nasdaq based on Listing Rule 5450(a)(1), the Company's securities will be delisted from the Nasdaq Stock Market. The Company does not intend to appeal Nasdaq's determination. Trading of the Company's common st

      7/21/23 4:01:00 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ViewRay® Files Voluntary Chapter 11 Petitions

      Debtor-in-Possession Financing Secured to Support Ongoing Operations and Chapter 11 Process DENVER, July 17, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today that it and certain of its subsidiaries (collectively, "the Company") filed voluntary petitions for relief (the "Petitions") under Chapter 11 of Title 11 the U.S. Bankruptcy Code ("Chapter 11") in the United States Bankruptcy Court for the District of Delaware (the "Court"). The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, including a sale of all or a portion of the Company's assets, while continuing to support its customers during the Chapter 11 pro

      7/17/23 7:00:00 AM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VRAY
    Financials

    Live finance-specific insights

    See more
    • ViewRay Announces First Quarter 2023 Results

      DENVER, May 10, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights Total revenue for the first quarter 2023 was approximately $22.5 million, primarily from three revenue units, compared to approximately $18.9 million, primarily from three revenue units, in the first quarter of 2022.Received 13 new orders for MRIdian systems, totaling $68.3 million.Total backlog increased to $411.0 million as of March 31, 2023, compared to approximately $331.0 million as of March 31, 2022.Cash and cash equivalents, inclusive of restricted cash, was $85.5 million as of March 31, 2023.Net l

      5/10/23 4:01:00 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ViewRay Announces Conference Call for First Quarter 2023 Financial Results to be Held After Market on May 10, 2023

      DENVER, May 9, 2023 /PRNewswire/ --ViewRay, Inc. (NASDAQ:VRAY) announced today details relating to the release of first quarter 2023 financial results. ViewRay will hold a conference call to discuss results on Wednesday, May 10, 2023 at 4:30 p.m. ET. The dial-in number is (833) 470-1428 for domestic callers. The confirmation number is 133683. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at https://investors.viewray.com/events-and-webinars. After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website under "Events and Webinars." About ViewRay® ViewRay, Inc. (NASDAQ:VRA

      5/9/23 4:10:00 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ViewRay Announces Conference Call for Preliminary First Quarter 2023 Financial Results to be held Pre-Market opening on April 13, 2023

      DENVER, April 12, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) will hold a conference call to discuss results on Thursday, April 13, 2023, at 8:00 AM ET. The dial-in number for domestic callers is (888) 886-7786. The confirmation number is 56031524. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at https://investors.viewray.com/events-and-webinars. After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website under "Events and Webinars". About ViewRay® ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MR

      4/12/23 5:25:00 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VRAY
    SEC Filings

    See more
    • SEC Form 25-NSE filed by ViewRay Inc.

      25-NSE - ViewRay, Inc. (0001597313) (Subject)

      9/8/23 10:12:09 AM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ViewRay Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ViewRay, Inc. (0001597313) (Filer)

      9/7/23 5:28:43 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form NT 10-Q filed by ViewRay Inc.

      NT 10-Q - ViewRay, Inc. (0001597313) (Filer)

      8/14/23 4:03:14 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VRAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ViewRay downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded ViewRay from Buy to Neutral and set a new price target of $1.00 from $4.00 previously

      5/11/23 6:49:02 AM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ViewRay downgraded by Jefferies with a new price target

      Jefferies downgraded ViewRay from Buy to Hold and set a new price target of $1.25 from $7.00 previously

      4/17/23 7:40:30 AM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ViewRay downgraded by Oppenheimer

      Oppenheimer downgraded ViewRay from Outperform to Perform

      4/14/23 8:06:57 AM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VRAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by ViewRay Inc. (Amendment)

      SC 13G/A - ViewRay, Inc. (0001597313) (Subject)

      2/14/24 4:50:48 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by ViewRay Inc. (Amendment)

      SC 13G/A - ViewRay, Inc. (0001597313) (Subject)

      2/12/24 6:26:25 AM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by ViewRay Inc. (Amendment)

      SC 13G/A - ViewRay, Inc. (0001597313) (Subject)

      2/7/24 6:13:01 AM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VRAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Shah Sanket

      4 - ViewRay, Inc. (0001597313) (Issuer)

      7/26/23 5:05:01 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Podbelski Adam Andrew

      4 - ViewRay, Inc. (0001597313) (Issuer)

      7/26/23 5:04:48 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 3: New insider Shah Sanket claimed ownership of 66,659 shares

      3 - ViewRay, Inc. (0001597313) (Issuer)

      7/26/23 5:03:11 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care